Haemagglutinin mutations and glycosylation changes shaped the 2012/13 influenza A(H3N2) epidemic, Houston, Texas

Eurosurveillance

Volumn 20, Issue 18, 2015, Pages

  Stucker, K M ^a   Schobel, S A ^a,b   Olsen, R J ^c   Hodges, H L ^a,d   Lin, X ^a   Halpin, R A ^a   Fedorova, N ^a   Stockwell, T B ^a   Tovchigrechko, A ^a   Das, S R ^a   Wentworth, D E ^a,e   Musser, J M ^c  

^a J CRAIG VENTER INSTITUTE   (United States)

^b University of Maryland   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS RNA;

ANTIGENICITY; ARTICLE; DISEASE SURVEILLANCE; EPIDEMIC; GENE MUTATION; GENE SEQUENCE; GENE SYNTHESIS; GLYCOSYLATION; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFLUENZA A (H3N2); NONHUMAN; PHYLOGENY; REVERSE GENETICS; VIRUS GENOME; VIRUS ISOLATION; DNA SEQUENCE; FEMALE; GENETIC DRIFT; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H3N2); INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MUTATION; TEXAS;

EPIDEMICS; FEMALE; GENETIC DRIFT; GLYCOSYLATION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MUTATION; PHYLOGENY; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TEXAS;

EID: 84929448802     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2015.20.18.21122     Document Type: Article

References (63)

1. World Health Organization (WHO). Influenza (Seasonal). Fact Sheet No.211. Geneva: WHO; March, 2014. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
2. Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem. 1987;56(1):365-94. http://dx.doi.org/10.1146/annurev.bi.56.070187.002053 PMID:3304138
3. Hay AJ, Gregory V, Douglas AR, Lin YP. The evolution of human influenza viruses. Philos Trans R Soc Lond B Biol Sci. 2001;356(1416):1861-70. http://dx.doi.org/10.1098/rstb.2001.0999 PMID:11779385
4. Stohr K, Bucher D, Colgate T, Wood J. Influenza virus surveillance, vaccine strain selection, and manufacture Methods Mol Biol. 2012;865:147-62. http://dx.doi.org/10.1007/978-1-61779-621-0_9 PMID:22528158
5. Ampofo WK, Al Busaidy S, Cox NJ, Giovanni M, Hay A, Huang S, et al.; WHO Writing Group. Strengthening the influenza vaccine virus selection and development process: outcome of the 2nd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at the Centre International de Conferences (CICG) Geneva, Switzerland, 7 to 9 December 2011. Vaccine. 2013;31(32):3209-21. http://dx.doi.org/10.1016/j.vaccine.2013.05.049 PMID:23685246
6. Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S, Edwards S, et al. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir Viruses. 2012;6(2):142-52. http://dx.doi.org/10.1111/j.1750-2659.2011.00277.x PMID:21819547
7. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, et al. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004;305(5682):371-6. http://dx.doi.org/10.1126/science.1097211 PMID:15218094
8. Das SR, Hensley SE, Ince WL, Brooke CB, Subba A, Delboy MG, et al. Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. Cell Host Microbe. 2013;13(3):314-23. http://dx.doi.org/10.1016/j.chom.2013.02.008 PMID:23498956
9. World Health Organization Regional Office for Europe (WHO/Europe). Summary of the 2012-2013 influenza season in the WHO European Region. Copenhagen: WHO/Europe; 2013. Available from: http://www.euro.who.int/en/health-topics/communicable-diseases/influenza/publications/2013/summary-of-the-20122013-influenza-season-in-the-whoeuropean-region
10. Review of the 2012-2013 winter influenza season, northern hemisphere. Wkly Epidemiol Rec. 2013;88(22):225-32.
11. Cockburn WC, Delon PJ, Ferreira W. Origin and progress of the 1968-69 Hong Kong influenza epidemic. Bull World Health Organ. 1969;41(3):345-8.
12. Westgeest KB, Russell CA, Lin X, Spronken MI, Bestebroer TM, Bahl J, et al. Genomewide analysis of reassortment and evolution of human influenza A(H3N2) viruses circulating between 1968 and 2011. J Virol. 2014;88(5):2844-57. http://dx.doi.org/10.1128/JVI.02163-13 PMID:24371052
13. Centers for Disease Control and Prevention (CDC). Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013. MMWR Morb Mortal Wkly Rep. 2013;62(7):119-23.
14. Bragstad K, Emborg H, Fischer TK, Voldstedlund M, Gubbels S, Andersen B, et al. Low vaccine effectiveness against influenza A(H3N2) virus among elderly people in Denmark in 2012/13- -a rapid epidemiological and virological assessment. Euro Surveill. 2013;18(6):11-7. PMID:23410258
15. Kelvin DJ, Farooqui A. Extremely low vaccine effectiveness against influenza H3N2 in the elderly during the 2012/2013 flu season. J Infect Dev Ctries. 2013;7(3):299-301. http://dx.doi.org/10.3855/jidc.3544 PMID:23493013
16. McMenamin J, Andrews N, Robertson C, Fleming D, Durnall H, von Wissmann B, et al. Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13. Euro Surveill. 2013;18(5):1-5. PMID:23399421
17. Skowronski DJN, De Serres G, Dickinson J, Winter A, Mahmud S, Sabaiduc S, et al. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada’s sentinel surveillance network, January 2013. Euro Surveill. 2013;18(5):1-10:20394.
18. Valenciano M, Kissling E.: I-MOVE Case-Control Study Team. Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012/13. Euro Surveill. 2013;18(7):3.
19. Nelson MI, Tan Y, Ghedin E, Wentworth DE, St George K, Edelman L, et al. Phylogeography of the spring and fall waves of the H1N1/09 pandemic influenza virus in the United States. J Virol. 2011;85(2):828-34. http://dx.doi.org/10.1128/JVI.01762-10 PMID:21068250
20. Chambers BS, Li Y, Hodinka RL, Hensley SE. Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses. J Virol. 2014;88(18):10986-9. http://dx.doi.org/10.1128/JVI.01077-14 PMID:24991002
21. State and county QuickFacts. Harris County, Texas. Washington: United States Census Bureau. [Accessed: 7 Oct 2014]. Available from: http://quickfacts.census.gov/qfd/states/48/48201.html
22. Emerson MO, Bratter J, Howell J, Jeanty PW, Cline M. Houston region grows more racially/ethnically diverse, with small declines in segregation. A joint report analyzing census data from 1990, 2000, and 2010. Houston: Rice University; 2012. Available from: http://kinder.rice.edu/uploadedFiles/Urban_Research_Center/Media/Houston%20Region%20Grows%20More%20Ethnically%20Diverse%202-13.pdf
23. Zhou B, Wentworth DE. Influenza A virus molecular virology techniques. Methods Mol Biol. 2012;865:175-92. http://dx.doi.org/10.1007/978-1-61779-621-0_11 PMID:22528160
24. Zhou B, Donnelly ME, Scholes DT, St George K, Hatta M, Kawaoka Y, et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J Virol. 2009;83(19):10309-13. http://dx.doi.org/10.1128/JVI.01109-09 PMID:19605485
25. Cox NJ. Seasonal influenza and zoonotic influenza. Information for the vaccine and related biological products advisory committee meeting. Silver Spring, Maryland; 28 Feb 2012. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM300419.pptx
26. McCauley J, Daniels R, Lin YP, Xiang Z, Gregory V, Whittaker L, et al. Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Southern Hemisphere 2013. 2012. Available from: http://www.crick.ac.uk/media/221897/interim_report_september_2012_2.pdf
27. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 2002;30(14):3059-66. http://dx.doi.org/10.1093/nar/gkf436 PMID:12136088
28. Katoh K, Toh H. Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinform. 2008;9(4):286-98. http://dx.doi.org/10.1093/bib/bbn013 PMID:18372315
29. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol. 2013;30(4):772-80. http://dx.doi.org/10.1093/molbev/mst010 PMID:23329690
30. Bazinet AL, Cummings MP. The Lattice Project: a grid research and production environment combining multiple grid computing models. In: Weber MHW, editor. Distributed & Grid Computing - Science Made Transparent for Everyone Principles, Applications and Supporting Communities. Marburg, Germany: Rechenkraft.net; 2008. p. 2-13.
31. Zwickl DJ. Genetic algorithm approaches for the phylogenetic analysis of large biological sequence datasets under the maximum likelihood criterion. [Thesis]. Austin: The University of Texas; 2006. Available from: http://repositories.lib.utexas.edu/handle/2152/2666
32. Sukumaran J, Holder MT. DendroPy: a Python library for phylogenetic computing. Bioinformatics. 2010;26(12):1569-71. http://dx.doi.org/10.1093/bioinformatics/btq228 PMID:20421198
33. Darriba D, Taboada GL, Doallo R, Posada D. jModelTest 2: more models, new heuristics and parallel computing. Nat Methods. 2012;9(8):772. http://dx.doi.org/10.1038/nmeth.2109 PMID:22847109
34. Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol. 2003;52(5):696-704. http://dx.doi.org/10.1080/10635150390235520 PMID:14530136
35. Abascal F, Zardoya R, Posada D. ProtTest: selection of best-fit models of protein evolution. Bioinformatics. 2005;21(9):2104-5. http://dx.doi.org/10.1093/bioinformatics/bti263 PMID:15647292
36. Li K, Venter E, Yooseph S, Stockwell TB, Eckerle LD, Denison MR, et al. ANDES: Statistical tools for the ANalyses of DEep Sequencing. BMC Res Notes. 2010;3(1):199. http://dx.doi.org/10.1186/1756-0500-3-199 PMID:20633290
37. Schobel-McHugh R. OrionPlot. GitHub, Inc.; 2014. Available from: https://github.com/sschobel/orion-plot/tree/master/OrionPlot/dist/alpha
38. Dormitzer PR, Suphaphiphat P, Gibson DG, Wentworth DE, Stockwell TB, Algire MA, et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med. 2013;5(185):185ra68. http://dx.doi.org/10.1126/scitranslmed.3006368 PMID:23677594
39. World Health Organization (WHO). Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza. Geneva: WHO; 2011. Available from: http://www.who.int/influenza/gisrs_laboratory/manual_diagnosis_surveillance:influenza/en/
40. Lin YP, Xiong X, Wharton SA, Martin SR, Coombs PJ, Vachieri SG, et al. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci U S A. 2012;109(52):21474-9. http://dx.doi.org/10.1073/pnas.1218841110 PMID:23236176
41. Guttman M, Weinkam P, Sali A, Lee KK. All-atom ensemble modeling to analyze small-angle x-ray scattering of glycosylated proteins. Structure. 2013;21(3):321-31. http://dx.doi.org/10.1016/j.str.2013.02.004 PMID:23473666
42. Guvench O, Greene SN, Kamath G, Brady JW, Venable RM, Pastor RW, et al. Additive empirical force field for hexopyranose monosaccharides. J Comput Chem. 2008;29(15):2543-64. http://dx.doi.org/10.1002/jcc.21004 PMID:18470966
43. Guvench O, Hatcher ER, Venable RM, Pastor RW, Mackerell AD. CHARMM Additive All-Atom Force Field for Glycosidic Linkages between Hexopyranoses. J Chem Theory Comput. 2009;5(9):2353-70. http://dx.doi.org/10.1021/ct900242e PMID:20161005
44. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234(3):779-815. http://dx.doi.org/10.1006/jmbi.1993.1626 PMID:8254673
45. Schrodinger L. The PyMOL Molecular Graphics System, Version 1.7.1.7. 2010.
46. Tovchigrechko A. Modeling and visualization of influenza hemagglutinin glycosylation. Sydney: Atlassian; 2015 Available from: https://bitbucket.org/andreyto/flu_ha_glyc
47. McCauley J, Daniels R, Lin YP, Xiang Z, Gregory V, Whittaker L, et al. Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Southern Hemisphere 2015. 2014. Available from: http://www.crick.ac.uk/media/221823/nimr-vcm-report-sep-14-web.pdf
48. Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol. 2010;84(13):6769-81. http://dx.doi.org/10.1128/JVI.00458-10 PMID:20410266
49. Neverov AD, Lezhnina KV, Kondrashov AS, Bazykin GA. Intrasubtype reassortments cause adaptive amino acid replacements in H3N2 influenza genes. PLoS Genet. 2014;10(1):e1004037. http://dx.doi.org/10.1371/journal.pgen.1004037 PMID:24415946
50. Rambaut A, Pybus OG, Nelson MI, Viboud C, Taubenberger JK, Holmes EC. The genomic and epidemiological dynamics of human influenza A virus. Nature. 2008;453(7195):615-9. http://dx.doi.org/10.1038/nature06945 PMID:18418375
51. Hale BG, Randall RE, Ortin J, Jackson D. The multifunctional NS1 protein of influenza A viruses. J Gen Virol. 2008;89(Pt 10):2359-76. http://dx.doi.org/10.1099/vir.0.2008/004606-0 PMID:18796704
52. Haye K, Burmakina S, Moran T, Garcia-Sastre A, Fernandez- Sesma A. The NS1 protein of a human influenza virus inhibits type I interferon production and the induction of antiviral responses in primary human dendritic and respiratory epithelial cells. J Virol. 2009;83(13):6849-62. http://dx.doi.org/10.1128/JVI.02323-08 PMID:19403682
53. McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015;211(10):1529-40. PMID:25406334
54. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342(6161):976-9. http://dx.doi.org/10.1126/science.1244730 PMID:24264991
55. Shakin-Eshleman SH, Spitalnik SL, Kasturi L. The amino acid at the X position of an Asn-X-Ser sequon is an important determinant of N-linked core-glycosylation efficiency. J Biol Chem. 1996;271(11):6363-6. http://dx.doi.org/10.1074/jbc.271.11.6363 PMID:8626433
56. Wanzeck K, Boyd KL, McCullers JA. Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice. Am J Respir Crit Care Med. 2011;183(6):767-73. http://dx.doi.org/10.1164/rccm.201007-1184OC PMID:20935106
57. Arinaminpathy N, Grenfell B. Dynamics of glycoprotein charge in the evolutionary history of human influenza. PLoS One. 2010;5(12):e15674. http://dx.doi.org/10.1371/journal.pone.0015674 PMID:21209885
58. Kobayashi Y, Suzuki Y. Evidence for N-glycan shielding of antigenic sites during evolution of human influenza A virus hemagglutinin. J Virol. 2012;86(7):3446-51. http://dx.doi.org/10.1128/JVI.06147-11 PMID:22258255
59. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2015 southern hemisphere influenza season. Geneva: WHO; 2014. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2015_south/en/
60. Daniels RS, Douglas AR, Skehel JJ, Wiley DC. Analyses of the antigenicity of influenza haemagglutinin at the pH optimum for virus-mediated membrane fusion. J Gen Virol. 1983;64(Pt 8):1657-62.http://dx.doi.org/10.1099/0022-1317-64-8-1657 PMID:6192202.
61. Popova L, Smith K, West AH, Wilson PC, James JA, Thompson LF, et al. Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS One. 2012;7(7):e41895. http://dx.doi.org/10.1371/journal.pone.0041895 PMID:22848649
62. Stray SJ, Pittman LB. Subtype- and antigenic site-specific differences in biophysical influences on evolution of influenza virus hemagglutinin. Virol J. 2012;9(1):91. http://dx.doi.org/10.1186/1743-422X-9-91 PMID:22569196
63. Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature. 1981;289(5796):373-8. http://dx.doi.org/10.1038/289373a0 PMID:6162101